Clinical Trial Update: Study to Investigate the Chemotherapy-Induced Peripheral Neuropathy (CIPN) Onset-Suppressing Effect and Safety of ONO-2910 in Patients With Breast Cancer Receiving Weekly Paclitaxel [Phase 2]

View source ↗

Summary

Phase 2 study evaluating ONO-2910 for suppressing the onset of chemotherapy-induced peripheral neuropathy in breast cancer patients receiving weekly paclitaxel;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Chemotherapy-induced Peripheral Neuropathy

Drugs mentioned

• ONO-2910 (ONO-2910)

Snippet

Sponsor: Ono Pharmaceutical Co., Ltd. | Conditions: CIPN - Chemotherapy-Induced Peripheral Neuropathy | Phase 2 | Status: COMPLETED